Abstract 1885P
Background
Pexa-vec (PV) is an oncolytic and immunotherapeutic vaccinia virus engineered to express GM-CSF. The REN026 study assessed the antitumor activity and safety of intravenous (IV) or intratumoral(IT) PV in combination with cemiplimab (REGN2810, anti-PD-1 inhibitor) in patients with metastatic or unresectable renal cell carcinoma (RCC).
Methods
The study enrolled 89 patients with measurable histologically or cytologically confirmed metastatic or unresectable RCC, randomly assigned to one of four study arms. Patients who were treatment-naive to immune check point inhibitors (ICIs) with accessible tumors were randomized into Arm A (IT PV and cemiplimab) or Arm B (cemiplimab monotherapy, upon disease progression PV (IT) was added. Patients who were treatment-naïve to ICIs with non-accessible tumors were assigned to Arm C with IV PV, and those with prior treatment with ICIs were assigned to Arm D with IV PV. PV was given IT (Arms A and B) administered every 2 weeks or IV (Arms C and D) weekly for 3 or 4 treatments as 1× 109 pfu. Cemiplimab IV infusion (all arms) was administered every 3 weeks, at a dose of 350 mg.
Results
Between June 2018 and October 2022, 89 patients were assigned to the study arms as follows: 15 in Arm A, 16 in Arm B, 30 in Arm C, and 28 in Arm D. The median number of prior systemic regimens in the metastatic setting was 1 (0-4) in Arms A, B, and C and 3 (1-5) in Arm D. With the median follow-up of 22.2 months, efficacy outcomes are shown in table. The most common treatment-related adverse event was pyrexia, with a Grade ≥ 3 of 13.3% in Arm A, 0% in Arm B,0% in Arm C, and 3.6% in Arm D. No Grade 5 events occurred in any of the study arms. Table: 1885P
Summary of efficacy results
A (n=15) | B (n=16) | C (n=30) | D (n=28) | |
IT | IV | |||
ORR (95% CI)-% | 13.3 (1.7-40.5) | 12.5 (1.6-38.4) | 23.3 (9.9-42.3) | 17.9 (6.1-36.9) |
DCR (95% CI)-% | 60.0 (32.3-83.7) | 56.2 (29.9-80.3) | 60.0 (40.6-77.3) | 67.9 (47.7-84.1) |
PFS median (mo) (80% CI) | 4.3 (3.3-6.3) | 5.6 (2.1-NA) | 4.8 (4.4-8.3) | 6.4 (3.6-12.3) |
OS median (mo) (80% CI) | 22.0 (22.0-NE) | 20.8 (19.5-NE) | 25.1 (22.7-NE) | 18.5 (14.8-NE) |
Median duration of response (range,months) | 6.1 (3.7-8.5) | 7.7 (4.1-11.3) | 10.4 (5.5-24.1) | 8.5 (1.1-11.3) |
Conclusions
The combination immunotherapy of IV PV and cemiplimab demonstrated an acceptable safety profile and encouraging efficacy of ORR and survival with durable responses in patients with metastatic or unresectable RCC, regardless of previous ICI treatment.
Clinical trial identification
NCT03294083.
Editorial acknowledgement
Acknowledgments: None
Legal entity responsible for the study
SillaJen Inc.
Funding
SillaJen Inc
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23